Description
Orlijon (Orlistat) 60 mg
Orlijon 60 mg is a brand-name product identified as orlistat 60 mg capsules. Orlistat is a medicine used for weight management in adults, and its effect comes from reducing the amount of dietary fat absorbed from the intestine.
Active Ingredient and Medicine Class
The verified active ingredient is orlistat. It is a gastrointestinal lipase inhibitor and an anti-obesity medicine. Its action is local in the gut rather than systemic.
Established Medical Uses
Official product information for orlistat 60 mg capsules describes use as a weight loss aid in overweight adults, together with a reduced-calorie, low-fat diet. Clinical studies and regulatory documents support its role in promoting weight loss and helping prevent weight regain when used as part of a structured diet plan.
How It Works
Orlistat blocks gastric and pancreatic lipases in the stomach and small intestine. This reduces the breakdown of dietary triglycerides into absorbable fatty acids and monoglycerides, so less fat is absorbed and more is excreted in the stool. The effect is due to local enzyme inhibition in the digestive tract.
Important Safety Information
Orlistat should not be used in people with chronic malabsorption syndrome or cholestasis. It is also contraindicated in people who are allergic to orlistat or any capsule ingredients, and it is not recommended during breastfeeding. Product information warns that orlistat can interact with cyclosporine, warfarin and other anticoagulants, levothyroxine, amiodarone, some antiepileptic medicines, and acarbose. It may also affect absorption of fat-soluble vitamins, and clinically important liver, kidney, and transplant-related safety issues have been reported in regulatory labeling.
Possible Side Effects
Common adverse effects are mainly gastrointestinal and reflect its mechanism of reducing fat absorption. These include oily or fatty stools, urgent need to open the bowels, increased bowel movements, abdominal discomfort, flatulence with discharge, and fecal spotting. Less common but important serious reactions include hypersensitivity, liver injury, and kidney-related complications.
Scientific Evidence
Randomized controlled trials found that orlistat, used with dietary intervention, produced greater weight loss and less weight regain than placebo over 2 years, with some improvement in obesity-related risk factors. Systematic reviews also found benefits for weight loss compared with placebo, while gastrointestinal adverse events were more frequent.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet, prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / FDA — ALLI (orlistat) capsule label
- Medicines.org.uk (emc) — alli 60 mg hard capsules, Summary of Product Characteristics
- Sjöström L, et al. — Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group — Lancet, 1998
